Inhibitor of cholesterol biosynthesis may have potential as breast cancer treatment

Share this content:

A compound initially developed as a treatment for high cholesterol not only halts the progression of breast cancer, but also can kill cancer cells. All animal cells contain cholesterol, which serves as a structural component of cell membranes.

“Because tumor cells grow rapidly they need to synthesize more cholesterol. Scientists working to cure breast cancer often seek out alternative targets that might slow or stop the progression of the disease, including the elimination of cancerous cells. We targeted the production of cholesterol in cancer cells which caused the death of breast cancer cells,” said Salman Hyder, PhD, Department of Biomedical Sciences, University of Missouri, Columbia.

Up to 70% of breast cancers in women are hormone-dependent and can be treated with antihormone medicines such as tamoxifen. Although tumor cells may respond to this type of therapy initially, most tumors eventually develop resistance to the medication, allowing breast cancer cells to grow and spread.

Cholesterol may contribute to the development of resistance to antihormone medications because cholesterol can be converted to hormones in tumor cells. Therefore, these cholesterol-forming pathways are attractive targets in the treatment of breast cancer.

Hyder and his team tested a compound developed for the treatment of high cholesterol on human breast cancer cells grown in the laboratory. The compound reduced the growth of human breast cancer cells and often caused the cancer cells to die. In addition, the cholesterol-lowering drug destroyed an estrogen receptor that facilitates tumor cell growth. The cholesterol-lowering drug had no effect on the viability of normal human breast cells grown in the laboratory.

When the cholesterol-lowering drug was tested in mice with breast cancer, the compound killed breast cancer cells by reducing the presence of estrogen receptors on the tumor cells.

“The compound exhibited antitumor properties in both human samples and in samples that were administered by injection into the mice,” Hyder said. “In both cases, the estrogen receptors that cause tumors to grow were eliminated, leading to more rapid cell death.”

Further clinical testing may lead to a drug with the dual properties of fighting high cholesterol and treating breast cancer that is sensitive to hormones.

This study was published in Breast Cancer Research and Treatment (2014; doi:10.1007/s10549-014-2996-5).

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs